In sickle cell disease management, vaso-occlusive pain crises arise from tissue ischemia caused by episodic vascular occlusion, and are mechanistically distinct from the chronic pain, opioid tolerance, dependency, and hyperalgesia that can develop from repeated exposure to opioid therapy over the disease course; effective management requires distinguishing acute-on-chronic pain from independent acute episodes and pairing opioid dosing (individualized by drug half-life and prior opioid exposure) with adjunctive non-opioid and non-pharmacologic strategies. The disease's underlying single-gene mutation manifests through multiple distinct pathophysiological pathways (hemoglobin polymerization, inflammatory, oxidative, and vaso-adhesive), each targeted by a different class of disease-modifying therapy, while curative approaches center on hematopoietic stem cell transplantation and emerging gene therapy strategies.
In sickle cell disease management, vaso-occlusive pain crises arise from tissue ischemia caused by episodic vascular occlusion, and are mechanistically distinct from the chronic pain, opioid toleranc…